Please login to the form below

Not currently logged in
Email:
Password:

Galapagos awarded milestone payment from Boehringer Ingelheim

Belgium based genomic drug discovery company Galapagos has revealed that its BioFocus DPI service division received a milestone payment in the autoimmune discovery research collaboration with Boehringer Ingelheim.

Belgium based genomic drug discovery company Galapagos has revealed that its BioFocus DPI service division received a milestone payment in the autoimmune discovery research collaboration with Boehringer Ingelheim.

The three-year collaboration announced in January 2006 involves an expansion of BioFocus DPI's SilenceSelect RNA based gene collection with an additional gene set, the development of a dedicated cellular assay in the field of autoimmune diseases, and its application in a target discovery screen for Boehringer Ingelheim's autoimmune discovery research.

Galapagos obtained upfront fees and will continue to receive R&D funding, and will receive milestone fees when certain drug discovery criteria are met. Should all criteria on a target be achieved, total potential contract value for Galapagos coudl exceed EUR 2m (USD 2.7m).

Onno van de Stolpe, CEO of Galapagos, said: "This milestone speaks to BioFocus DPI's ability to deliver on longer term, higher value collaborations. We are delighted that the collaboration with Boehringer Ingelheim has progressed as planned and is on track to continue delivering value."

25th July 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics